Notably, a robust synergistic antileukemic effect was observed with the combination of ponatinib and asciminib in CML-BC cell lines and CML-BC stem cells carrying the BCR::ABL1 T315I mutation [10]. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.